ConductScience.org, home

Gene · 8754

ADAM9: ADAM metallopeptidase domain 9

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. ADAM9: ADAM metallopeptidase domain 9. Genes, record 8754. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/8754

On this page

Gene

Symbol
ADAM9
HGNC
Name
ADAM metallopeptidase domain 9
HGNC
NCBI Gene ID
8754
NCBI Gene
HGNC ID
HGNC:216
HGNC
Ensembl
ENSG00000168615
NCBI Gene
Aliases
CORD9, KIAA0021, MCMP, MDC9, Mltng
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q13443Disintegrin and metalloproteinase domain-containing protein 98190Ensembl, GeneID, HGNC

Source UniProt

Patents96

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
EP 4780859 A12026-07-292Q13443Espacenet
JP 2026515744 A2026-05-19148Q13443Espacenet
JP 2026004568 A2026-01-1436441Q13443Espacenet
EP 4653464 A22025-11-265Q13443Espacenet
EP 4650780 A22025-11-1914331Q13443Espacenet
EP 4641201 A22025-10-2916763Q13443Espacenet
EP 4641202 A22025-10-29911Q13443Espacenet
EP 4641203 A22025-10-29515Q13443Espacenet
JP 2025147176 A2025-10-06308Q13443Espacenet
JP 2025529142 A2025-09-04280Q13443Espacenet

1 to 10 of 96

See all 96 patents

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants969

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleADAM9 papersNewest fiscal year
P30CA008748Cancer Center Support Grant72025
P30CA016672Cancer Center Support Grant42025
P30CA076292Moffitt Cancer Center Support Grant42025
P30EY010572Ophthalmology Core Facility32025
R01EY006855Models for Therapy of Hereditary Retinal Degeneration32025
ZIABC006150DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs32025
K24AR060297Scleroderma Twin Study and analysis of Estrogen in patients with dcSSc22025
P01AI063302The intersection of innate and adaptive immunity to intracellular pathogens22025
P30CA014051Cancer Center Support (Core) Grant22025
P30CA016056Roswell Park Cancer Center Support Grant22025

1 to 10 of 969Source NIH's project files

See all 969 nih grants

Papers1,799

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Identification and functional experimental verification of efferocytosis-related diagnostic biomarkers for sepsis.Int J Biochem Cell Biol202642777907PubTator, text miningPubMed
Mechanisms related to increased susceptibility of the elderly lung to ventilator-induced lung injury: A scoping review.Exp Gerontol202642735803PubTator, text miningPubMed
Dissecting the Transcriptomic Profile of CD163+ Macrophages in Hepatocellular Carcinoma with VETC+ Angiogenesis Provides Potential Targets of Treatment.Liver Cancer202642524682PubTator, text miningPubMed
Collagen XVIIα1 in skin and hair aging: Mechanisms, stem cell niche regulation, and translational strategies.J Dermatol Sci202642276855PubTator, text miningPubMed
Multi-omics profiling identifies ADAM9 as a key efferocytosis driver in lung adenocarcinoma.Front Immunol202642266684PubTator, text miningPubMed
Adam13 interacts with large protein complexes to regulate histone modification and gene expression.Front Cell Dev Biol202642181688PubTator, text miningPubMed
ADAM9: an updated view of its biology and pathology.Mol Biol Rep202642171934PubTator, text miningPubMed
A Theranostic Study of 177Lu-Labeled Anti-ADAM9 Antibody for the Treatment of Triple-Negative Breast Cancer.Bioconjug Chem202642155035PubTator, text miningPubMed
Evaluation of translational potential of mRNA vaccine candidate antigens for pancreatic cancer: a systematic review based on clinical evidence and stratified prioritization strategies.Front Immunol202642131338PubTator, text miningPubMed
M2 Macrophage membrane-mediated biomimetic nanoparticles carrying ADAM9 siRNA alleviate renal inflammation and fibrosis via the AKT/NF-κB pathway.J Nanobiotechnology202642116024PubTator, text miningPubMed

1 to 10 of 1,799

See all 1,799 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/8754

GET https://conductscience.org/api/genes/v1/8754/patents?page=2